Trial
NCT01810913
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
NRG Oncology
Condition
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Intervention
Atezolizumab
Why stopped
Other - Assessing accrual feasibility
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-31